Search

Your search keyword '"Jimenez-Zepeda, Victor H."' showing total 467 results
Start Over Author "Jimenez-Zepeda, Victor H."
467 results on '"Jimenez-Zepeda, Victor H."'

1. Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database

Author

Venner, Christopher P., Duggan, Peter, Song, Kevin, Reece, Donna, Sharma, Smriti, Su, Jiandong, Jimenez-Zepeda, Victor H., McCurdy, Arleigh, Louzada, Martha, Mian, Hira, Sebag, Michael, White, Darrell, Stakiw, Julie, Kotb, Rami, Aslam, Muhammad, Reiman, Anthony, Gul, Engin, Chu, Michael P., Bergstrom, Debra, and LeBlanc, Richard

Published
2024
Full Text
View/download PDF

2. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database

Author

Côté, Julie, LeBlanc, Richard, Mian, Hira, Chu, Michael P., McCurdy, Arleigh, Masih-Khan, Esther, Su, Jiandong, Jimenez-Zepeda, Victor H., Song, Kevin, Louzada, Martha, White, Darrell, Sebag, Michael, Reiman, Anthony, Stakiw, Julie, Kotb, Rami, Bergstrom, Debra, Aslam, Muhammad, Kaedbey, Rayan, Venner, Christopher P., Gul, Engin, and Reece, Donna

Published
2023
Full Text
View/download PDF

8. Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database

Author

Mian, Hira, Reece, Donna, Masih-Khan, Esther, McCurdy, Arleigh, Kardjadj, Moustafa, Jimenez-Zepeda, Victor H, Song, Kevin, Louzada, Martha, LeBlanc, Richard, Sebag, Michael, White, Darrell, Stakiw, Julie, Reiman, Anthony, Kotb, Rami, Aslam, Muhammad, Gul, Engin, and Venner, Christopher P.

Published
2022
Full Text
View/download PDF

9. Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.

Author

Lewis, Ellen, Fine, Nowell, McCulloch, Sylvia, Tay, Jason, Duggan, Peter, Neri, Paola, Bahlis, Nizar, and Jimenez-Zepeda, Victor H.

Subjects
PROGRESSION-free survival, AMYLOIDOSIS, CARDIAC patients, DOXYCYCLINE, CARDIAC amyloidosis, BORTEZOMIB
Abstract

Background: Pre-clinical and retrospective data suggest that doxycycline added to treatment regimens has benefit in AL amyloidosis. However, a recent multicenter, open-label, randomized controlled trial in AL amyloidosis patients treated with CyBorD did not demonstrate a progression-free survival (PFS) or cardiac PFS benefit with added doxycycline. Objective: The main objective of this study was to explore the role of doxycycline combined with bortezomib-containing regimens (BCRs) for newly diagnosed AL amyloidosis patients with cardiac involvement and to compare them with a cohort of concurrent patients treated with BCR only. Material and Methods: AL amyloidosis patients, newly diagnosed between January 2012 and March 2022, who were treated with BCR at the Amyloidosis Program of Calgary (APC) were evaluated. Results: Sixty-four concurrent patients were identified. Thirty-nine patients received doxycycline in addition to BCR (BCR-D) for a median of 8 months. The overall response rate was similar among the groups. No significant differences in VGPR/CR, dFLC at 1 month, time to first response, time to best response, or organ responses were noted between the BCR alone and BCR-D groups. Summary and Conclusions: Our retrospective study demonstrated that doxycycline combined with BCR failed to prolong OS, PFS, or cardiac responses compared with BCR alone in patients with cardiac AL amyloidosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database

Author

Kaedbey, Rayan, Reece, Donna, Venner, Christopher P., McCurdy, Arleigh, Su, Jiandong, Chu, Michael, Louzada, Martha, Jimenez‐Zepeda, Victor H, Mian, Hira, Song, Kevin, Sebag, Michael, Stakiw, Julie, White, Darrell, Reiman, Anthony, Aslam, Muhammad, Kotb, Rami, Bergstrom, Debra, Gul, Engin, and LeBlanc, Richard

Published
2024
Full Text
View/download PDF

15. Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC).

Author

Levin, Daniel, Lewis, Ellen, McCulloch, Sylvia, Lee, Holly, Tay, Jason, Duggan, Peter, Neri, Paola, Bahlis, Nizar, and Jimenez-Zepeda, Victor H.

Subjects
CARDIAC amyloidosis, DARATUMUMAB, AMYLOIDOSIS, IMMUNOGLOBULIN light chains, CLINICAL trials
Abstract

A letter to the editor discusses the use of daratumumab, a monoclonal antibody, for the treatment of relapsed/refractory AL amyloidosis. The letter highlights the traditional treatment of AL amyloidosis using bortezomib, cyclophosphamide, and dexamethasone, but notes that this regimen is less effective in patients with cytogenetic abnormalities. The letter then discusses the approval of daratumumab in combination with CyBorD as upfront treatment for newly diagnosed AL amyloidosis. The study conducted a retrospective analysis of 23 patients with relapsed or refractory AL amyloidosis who received daratumumab-containing regimens and found that 95% of patients achieved hematologic responses and 59% achieved organ responses. The median progression-free survival and overall survival have not been reached yet. A retrospective study was conducted on 23 patients with relapsed/refractory AL amyloidosis to evaluate the effectiveness of daratumumab-based therapy. The results showed that 96% of patients achieved a hematologic response, 53% achieved a cardiac response, and 36% achieved a renal response. The study also found that patients treated with daratumumab, lenalidomide, and dexamethasone had a higher hematologic response rate compared to other regimens. However, the study had limitations due to its small sample size and retrospective nature. Overall, the findings provide real-world support for the [Extracted from the article]

Published
2024
Full Text
View/download PDF

20. Long‐term survivorship care after CAR‐T cell therapy.

Author

Puckrin, Robert, Jamani, Kareem, and Jimenez‐Zepeda, Victor H.

Subjects
CELLULAR therapy, IMMUNE reconstitution inflammatory syndrome, CYTOKINE release syndrome, LONG-term health care, CHIMERIC antigen receptors, PSYCHOLOGICAL distress
Abstract

While cytokine release syndrome and immune effector cell‐associated neurotoxicity syndrome are well‐recognized acute toxicities of chimeric antigen receptor (CAR) T cell therapy, these complications have become increasingly manageable by protocolized treatment algorithms incorporating the early administration of tocilizumab and corticosteroids. As CAR‐T cell therapy expands to new disease indications and the number of long‐term survivors steadily increases, there is growing recognition of the need to appropriately evaluate and manage the late effects of CAR‐T cell therapy, including late‐onset or persistent neurotoxicity, prolonged cytopenias, delayed immune reconstitution and infections, subsequent malignancies, organ dysfunction, psychological distress, and fertility implications. In this review, we provide a practical approach to the long‐term survivorship care of the CAR‐T cell recipient, with a focus on the optimal strategies to address the common and challenging late complications affecting this unique population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Supplementary Figure 1 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Author

Braggio, Esteban, primary, Keats, Jonathan J., primary, Leleu, Xavier, primary, Van Wier, Scott, primary, Jimenez-Zepeda, Victor H., primary, Valdez, Riccardo, primary, Schop, Roelandt F.J., primary, Price-Troska, Tammy, primary, Henderson, Kimberly, primary, Sacco, Antonio, primary, Azab, Feda, primary, Greipp, Philip, primary, Gertz, Morie, primary, Hayman, Suzanne, primary, Rajkumar, S. Vincent, primary, Carpten, John, primary, Chesi, Marta, primary, Barrett, Michael, primary, Stewart, A. Keith, primary, Dogan, Ahmet, primary, Bergsagel, P. Leif, primary, Ghobrial, Irene M., primary, and Fonseca, Rafael, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 4 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Author

Braggio, Esteban, primary, Keats, Jonathan J., primary, Leleu, Xavier, primary, Van Wier, Scott, primary, Jimenez-Zepeda, Victor H., primary, Valdez, Riccardo, primary, Schop, Roelandt F.J., primary, Price-Troska, Tammy, primary, Henderson, Kimberly, primary, Sacco, Antonio, primary, Azab, Feda, primary, Greipp, Philip, primary, Gertz, Morie, primary, Hayman, Suzanne, primary, Rajkumar, S. Vincent, primary, Carpten, John, primary, Chesi, Marta, primary, Barrett, Michael, primary, Stewart, A. Keith, primary, Dogan, Ahmet, primary, Bergsagel, P. Leif, primary, Ghobrial, Irene M., primary, and Fonseca, Rafael, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 5 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Author

Braggio, Esteban, primary, Keats, Jonathan J., primary, Leleu, Xavier, primary, Van Wier, Scott, primary, Jimenez-Zepeda, Victor H., primary, Valdez, Riccardo, primary, Schop, Roelandt F.J., primary, Price-Troska, Tammy, primary, Henderson, Kimberly, primary, Sacco, Antonio, primary, Azab, Feda, primary, Greipp, Philip, primary, Gertz, Morie, primary, Hayman, Suzanne, primary, Rajkumar, S. Vincent, primary, Carpten, John, primary, Chesi, Marta, primary, Barrett, Michael, primary, Stewart, A. Keith, primary, Dogan, Ahmet, primary, Bergsagel, P. Leif, primary, Ghobrial, Irene M., primary, and Fonseca, Rafael, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 6 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Author

Braggio, Esteban, primary, Keats, Jonathan J., primary, Leleu, Xavier, primary, Van Wier, Scott, primary, Jimenez-Zepeda, Victor H., primary, Valdez, Riccardo, primary, Schop, Roelandt F.J., primary, Price-Troska, Tammy, primary, Henderson, Kimberly, primary, Sacco, Antonio, primary, Azab, Feda, primary, Greipp, Philip, primary, Gertz, Morie, primary, Hayman, Suzanne, primary, Rajkumar, S. Vincent, primary, Carpten, John, primary, Chesi, Marta, primary, Barrett, Michael, primary, Stewart, A. Keith, primary, Dogan, Ahmet, primary, Bergsagel, P. Leif, primary, Ghobrial, Irene M., primary, and Fonseca, Rafael, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure Legends 1-2 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Author

Braggio, Esteban, primary, Keats, Jonathan J., primary, Leleu, Xavier, primary, Van Wier, Scott, primary, Jimenez-Zepeda, Victor H., primary, Valdez, Riccardo, primary, Schop, Roelandt F.J., primary, Price-Troska, Tammy, primary, Henderson, Kimberly, primary, Sacco, Antonio, primary, Azab, Feda, primary, Greipp, Philip, primary, Gertz, Morie, primary, Hayman, Suzanne, primary, Rajkumar, S. Vincent, primary, Carpten, John, primary, Chesi, Marta, primary, Barrett, Michael, primary, Stewart, A. Keith, primary, Dogan, Ahmet, primary, Bergsagel, P. Leif, primary, Ghobrial, Irene M., primary, and Fonseca, Rafael, primary

Published
2023
Full Text
View/download PDF

26. Data from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Author

Braggio, Esteban, primary, Keats, Jonathan J., primary, Leleu, Xavier, primary, Van Wier, Scott, primary, Jimenez-Zepeda, Victor H., primary, Valdez, Riccardo, primary, Schop, Roelandt F.J., primary, Price-Troska, Tammy, primary, Henderson, Kimberly, primary, Sacco, Antonio, primary, Azab, Feda, primary, Greipp, Philip, primary, Gertz, Morie, primary, Hayman, Suzanne, primary, Rajkumar, S. Vincent, primary, Carpten, John, primary, Chesi, Marta, primary, Barrett, Michael, primary, Stewart, A. Keith, primary, Dogan, Ahmet, primary, Bergsagel, P. Leif, primary, Ghobrial, Irene M., primary, and Fonseca, Rafael, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 1 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Author

Braggio, Esteban, primary, Keats, Jonathan J., primary, Leleu, Xavier, primary, Van Wier, Scott, primary, Jimenez-Zepeda, Victor H., primary, Valdez, Riccardo, primary, Schop, Roelandt F.J., primary, Price-Troska, Tammy, primary, Henderson, Kimberly, primary, Sacco, Antonio, primary, Azab, Feda, primary, Greipp, Philip, primary, Gertz, Morie, primary, Hayman, Suzanne, primary, Rajkumar, S. Vincent, primary, Carpten, John, primary, Chesi, Marta, primary, Barrett, Michael, primary, Stewart, A. Keith, primary, Dogan, Ahmet, primary, Bergsagel, P. Leif, primary, Ghobrial, Irene M., primary, and Fonseca, Rafael, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 7 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Author

Braggio, Esteban, primary, Keats, Jonathan J., primary, Leleu, Xavier, primary, Van Wier, Scott, primary, Jimenez-Zepeda, Victor H., primary, Valdez, Riccardo, primary, Schop, Roelandt F.J., primary, Price-Troska, Tammy, primary, Henderson, Kimberly, primary, Sacco, Antonio, primary, Azab, Feda, primary, Greipp, Philip, primary, Gertz, Morie, primary, Hayman, Suzanne, primary, Rajkumar, S. Vincent, primary, Carpten, John, primary, Chesi, Marta, primary, Barrett, Michael, primary, Stewart, A. Keith, primary, Dogan, Ahmet, primary, Bergsagel, P. Leif, primary, Ghobrial, Irene M., primary, and Fonseca, Rafael, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 2 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Author

Braggio, Esteban, primary, Keats, Jonathan J., primary, Leleu, Xavier, primary, Van Wier, Scott, primary, Jimenez-Zepeda, Victor H., primary, Valdez, Riccardo, primary, Schop, Roelandt F.J., primary, Price-Troska, Tammy, primary, Henderson, Kimberly, primary, Sacco, Antonio, primary, Azab, Feda, primary, Greipp, Philip, primary, Gertz, Morie, primary, Hayman, Suzanne, primary, Rajkumar, S. Vincent, primary, Carpten, John, primary, Chesi, Marta, primary, Barrett, Michael, primary, Stewart, A. Keith, primary, Dogan, Ahmet, primary, Bergsagel, P. Leif, primary, Ghobrial, Irene M., primary, and Fonseca, Rafael, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 2 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Author

Braggio, Esteban, primary, Keats, Jonathan J., primary, Leleu, Xavier, primary, Van Wier, Scott, primary, Jimenez-Zepeda, Victor H., primary, Valdez, Riccardo, primary, Schop, Roelandt F.J., primary, Price-Troska, Tammy, primary, Henderson, Kimberly, primary, Sacco, Antonio, primary, Azab, Feda, primary, Greipp, Philip, primary, Gertz, Morie, primary, Hayman, Suzanne, primary, Rajkumar, S. Vincent, primary, Carpten, John, primary, Chesi, Marta, primary, Barrett, Michael, primary, Stewart, A. Keith, primary, Dogan, Ahmet, primary, Bergsagel, P. Leif, primary, Ghobrial, Irene M., primary, and Fonseca, Rafael, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table 3 from Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's Macroglobulinemia

Author

Braggio, Esteban, primary, Keats, Jonathan J., primary, Leleu, Xavier, primary, Van Wier, Scott, primary, Jimenez-Zepeda, Victor H., primary, Valdez, Riccardo, primary, Schop, Roelandt F.J., primary, Price-Troska, Tammy, primary, Henderson, Kimberly, primary, Sacco, Antonio, primary, Azab, Feda, primary, Greipp, Philip, primary, Gertz, Morie, primary, Hayman, Suzanne, primary, Rajkumar, S. Vincent, primary, Carpten, John, primary, Chesi, Marta, primary, Barrett, Michael, primary, Stewart, A. Keith, primary, Dogan, Ahmet, primary, Bergsagel, P. Leif, primary, Ghobrial, Irene M., primary, and Fonseca, Rafael, primary

Published
2023
Full Text
View/download PDF

34. Low Counts of B Cells, Natural Killer Cells, Monocytes, Dendritic Cells, Basophils, and Eosinophils are Associated with Postengraftment Infections after Allogeneic Hematopoietic Cell Transplantation

Author

Podgorny, Peter J., Pratt, Laura M., Liu, Yiping, Dharmani-Khan, Poonam, Luider, Joanne, Auer-Grzesiak, Iwona, Mansoor, Adnan, Williamson, Tyler S., Ugarte-Torres, Alejandra, Hoegh-Petersen, Mette, Khan, Faisal M., Larratt, Loree, Jimenez-Zepeda, Victor H., Stewart, Douglas A., Russell, James A., Daly, Andrew, and Storek, Jan

Published
2016
Full Text
View/download PDF

38. Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data

Author

Jimenez-Zepeda, Victor H., primary, Reece, Donna, additional, Rigo, Rodrigo, additional, Gogna, Priyanka, additional, Kong, Shiying, additional, Hu, Xun Yang, additional, Chapani, Parv, additional, Cheung, Winson Y., additional, Brenner, Darren R., additional, Plante, Richard, additional, Shi, Kun, additional, Husain, Asad, additional, Ammann, Eric, additional, Tankala, Dipti, additional, and Boyne, Devon J., additional

Published
2022
Full Text
View/download PDF

39. The Canadian Registry for Amyloidosis Research: A National Multi-Disciplinary Registry for Real-World Evidence

Author

Venner, Christopher P., primary, Reece, Donna E., additional, Baker, Steven, additional, Bril, Vera, additional, Delgado, Diego, additional, Carr, Mervyn, additional, Giraldeau, Geneviève, additional, Hodgkinson, Victoria, additional, Jimenez-Zepeda, Victor H, additional, Laidlaw, Liam A., additional, Massie, Rami, additional, McWhinnie, Marsha, additional, Paterson, Ian, additional, Fine, Nowell, additional, and Davis, Margot, additional

Published
2022
Full Text
View/download PDF

40. Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Author

Leblanc, Richard, primary, Venner, Christopher P., additional, Masih-Khan, Esther, additional, Kardjadj, Moustafa, additional, Chu, Michael P., additional, Jimenez-Zepeda, Victor H, additional, McCurdy, Arleigh, additional, Song, Kevin, additional, Sebag, Michael, additional, Louzada, Martha L, additional, Mian, Hira S, additional, White, Darrell J, additional, Stakiw, Julie, additional, Kotb, Rami, additional, Reiman, Anthony, additional, Aslam, Muhammad, additional, Kaedbey, Rayan, additional, Gul, Engin, additional, and Reece, Donna E., additional

Published
2022
Full Text
View/download PDF

41. Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Author

Visram, Alissa, primary, De La Torre, Alfredo, additional, White, Darrell, additional, Kardjadj, Moustafa, additional, Masih-Khan, Esther, additional, Chu, Michael P., additional, Jimenez-Zepeda, Victor H, additional, McCurdy, Arleigh, additional, Leblanc, Richard, additional, Song, Kevin, additional, Mian, Hira S, additional, Louzada, Martha L, additional, Sebag, Michael, additional, Bergstrom, Debra, additional, Stakiw, Julie, additional, Reiman, Anthony, additional, Kotb, Rami, additional, Aslam, Muhammad, additional, Venner, Christopher P., additional, Kaedbey, Rayan, additional, Gul, Engin, additional, and Reece, Donna E., additional

Published
2022
Full Text
View/download PDF

42. Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Author

Cote, Julie, primary, Leblanc, Richard, additional, Chu, Michael P., additional, McCurdy, Arleigh, additional, Masih-Khan, Esther, additional, Kardjadj, Moustafa, additional, Jimenez-Zepeda, Victor H, additional, Song, Kevin, additional, Louzada, Martha L, additional, Mian, Hira S, additional, White, Darrell, additional, Sebag, Michael, additional, Reiman, Anthony, additional, Stakiw, Julie, additional, Kotb, Rami, additional, Bergstrom, Debra, additional, Aslam, Muhammad, additional, Kaedbey, Rayan, additional, Venner, Christopher P., additional, Gul, Engin, additional, and Reece, Donna E., additional

Published
2022
Full Text
View/download PDF

43. Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Author

Kaedbey, Rayan, primary, Hay, Kevin, additional, Masih-Khan, Esther, additional, Kardjadj, Moustafa, additional, McCurdy, Arleigh, additional, Chu, Michael P., additional, Jimenez-Zepeda, Victor H, additional, Leblanc, Richard, additional, Song, Kevin, additional, Mian, Hira S, additional, Louzada, Martha L, additional, Sebag, Michael, additional, Reiman, Anthony, additional, White, Darrell J, additional, Venner, Christopher P., additional, Stakiw, Julie, additional, Kotb, Rami, additional, Aslam, Muhammad, additional, Bergstrom, Debra, additional, Gul, Engin, additional, and Reece, Donna E., additional

Published
2022
Full Text
View/download PDF

44. Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database

Author

Mian, Hira, primary, LeBlanc, Richard, additional, Louzada, Martha, additional, Masih‐Khan, Esther, additional, McCurdy, Arleigh, additional, Venner, Christopher P., additional, Stakiw, Julie, additional, Kardjadj, Moustafa, additional, Jimenez‐Zepeda, Victor H., additional, Sebag, Michael, additional, White, Darrell, additional, Aslam, Muhammad, additional, Song, Kevin, additional, Reiman, Anthony, additional, Kotb, Rami, additional, Gul, Engin, additional, and Reece, Donna, additional

Published
2022
Full Text
View/download PDF

45. Understanding real‐world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population‐based cohort study

Author

Jimenez‐Zepeda, Victor H., primary, Reece, Donna, additional, Rigo, Rodrigo, additional, Gogna, Priyanka, additional, Kong, Shiying, additional, Hu, Xun Yang, additional, Chapani, Parv, additional, Cheung, Winson Y., additional, Brenner, Darren R., additional, Plante, Richard, additional, Shi, Kun, additional, Husain, Asad, additional, Tankala, Dipti, additional, and Boyne, Devon J., additional

Published
2022
Full Text
View/download PDF

47. Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database

Author

McCurdy, Arleigh, primary, Louzada, Martha, additional, Venner, Christopher P., additional, Visram, Alissa, additional, Masih‐Khan, Esther, additional, Kardjadj, Moustafa, additional, Jimenez‐Zepeda, Victor H., additional, LeBlanc, Richard, additional, Sebag, Michael, additional, Song, Kevin, additional, White, Darrell, additional, Mian, Hira, additional, Stakiw, Julie, additional, Reiman, Anthony, additional, Aslam, Muhammad, additional, Kotb, Rami, additional, Gul, Engin, additional, and Reece, Donna, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results